# Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19

> **NCT04824391** · PHASE2 · COMPLETED · sponsor: **Health Institutes of Turkey** · enrollment: 250 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ERUCOV-VAC 3 µg/0.5 ml Vaccine
- **BIOLOGICAL:** ERUCOV-VAC 6 µg/0.5 ml Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04824391
- **Lead sponsor:** Health Institutes of Turkey
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-10
- **Primary completion:** 2022-03-11
- **Final completion:** 2022-03-30
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2023-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824391, "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04824391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*